- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
Investors have turned away from biotech at a time when the sector is normally humming with presentations of new clinical data at springtime medical meetings.